Ngā hua rapu kaituhi :: APM

1

Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies mā Andrea S. Teague, Kian‐Huat Lim, Andrea Wang‐Gillam

I whakaputaina 2015

Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
2

Targeting RAS -mutant Cancers: Is ERK the Key? mā Meagan B. Ryan, Channing J. Der, Andrea Wang‐Gillam, Adrienne D. Cox

I whakaputaina 2015

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
3

Chemotherapy-associated Posterior Reversible Encephalopathy Syndrome mā Joan How, Margaret Blattner, Susan A. Fowler, Andrea Wang‐Gillam, Suzanne E. Schindler

I whakaputaina 2016

Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
4

Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study mā Katrina S. Pedersen, George P. Kim, Nathan R. Foster, Andrea Wang‐Gillam, Charles Erlichman, Robert R. McWilliams

I whakaputaina 2015

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
5

Neoadjuvant Therapy of Pancreatic Cancer: The Emerging Paradigm? mā Kian‐Huat Lim, Eugene H. Chung, Adeel S. Khan, Dengfeng Cao, David C. Linehan, Edgar Ben‐Josef, Andrea Wang‐Gillam

I whakaputaina 2012

Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
6

NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors mā Andrea Wang‐Gillam, Richard Hubner, Jens T. Siveke, Daniel D. Von Hoff, Bruce Belanger, Floris A. de Jong, Beloo Mirakhur, Li‐Tzong Chen

I whakaputaina 2019

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
7

Tumor–Stroma IL1β-IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer mā Daoxiang Zhang, Lin Li, Hongmei Jiang, Qiong Li, Andrea Wang‐Gillam, Jinsheng Yu, Richard Head, Jingxia Liu, Marianna B. Ruzinova, Kian‐Huat Lim

I whakaputaina 2018

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
8

Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models mā Hongmei Jiang, Ming Xu, Lin Li, Patrick Grierson, Paarth B. Dodhiawala, Maureen Highkin, Daoxiang Zhang, Qiong Li, Andrea Wang‐Gillam, Kian‐Huat Lim

I whakaputaina 2018

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
9

Myeloid-Derived Suppressor Cells: General Characteristics and Relevance to Clinical Management of Pancreatic Cancer mā Peter S. Goedegebuure, Jonathan B. Mitchem, Matthew R. Porembka, Marcus Tan, Brian A. Belt, Andrea Wang‐Gillam, William E. Gillanders, William G. Hawkins, David C. Linehan

I whakaputaina 2011

Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
10

Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma mā Daoxiang Zhang, Lin Li, Hongmei Jiang, Brett L. Knolhoff, A. Craig Lockhart, Andrea Wang‐Gillam, David G. DeNardo, Marianna B. Ruzinova, Kian‐Huat Lim

I whakaputaina 2016

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
11

$Population Pharmacokinetics of Fruquintinib, a Selective Oral Inhibitor of VEGFR ‐1, ‐2, and ‐3, in Patients with Refractory Metastatic Colorectal Cancer$

Population Pharmacokinetics of Fruquintinib, a Selective Oral Inhibitor of VEGFR ‐1, ‐2, and ‐3, in Patients with Refractory Metastatic Colorectal Cancer mā Xiaofei Zhou, Xiaoyan Yang, Boris Grinshpun, Adekemi Taylor, Laura E. Strong, Arvind Dasari, Andrea Wang‐Gillam, Jin Li, Rui‐Hua Xu, Neeraj Gupta, Caly Chien

I whakaputaina 2025

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
12

CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models mā Yu Zhu, Brett L. Knolhoff, Melissa A. Meyer, Timothy M. Nywening, Brian L. West, Jingqin Luo, Andrea Wang‐Gillam, S. Peter Goedegebuure, David C. Linehan, David G. DeNardo

I whakaputaina 2014

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
13

Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation mā Comron Hassanzadeh, Soumon Rudra, A. Bommireddy, William G. Hawkins, Andrea Wang‐Gillam, Ryan C. Fields, Bin Cai, Justin Park, Olga Green, Michael Roach, Lauren E. Henke, Hyun Kim

I whakaputaina 2020

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
14

$A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors$

A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tum... mā Manik Amin, Susan Minton, Patricia LoRusso, Smitha Krishnamurthi, Cheryl A. Pickett, Jared Lunceford, Darcy A. Hille, David Mauro, Mark N. Stein, Andrea Wang‐Gillam, Lauren Trull, A. Craig Lockhart

I whakaputaina 2015

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
15

CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocar... mā L-T. Chen, Andrea Wang‐Gillam, Y-S Shan, T. Macarulla Mercadé, Jan Blanc, Richard Hubner, C-F. Chiu, G. Schwartsmann, J. Siveke, Bruce Belanger, F. de Jong, K. Mamlouk, D. Von Hoff

I whakaputaina 2017

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
16

A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma mā Andrea Wang‐Gillam, Stacey M. Plambeck-Suess, Peter S. Goedegebuure, Peter O. Simon, Jonathan B. Mitchem, John R. Hornick, Steven Sorscher, Joel Picus, Rama Suresh, A. Craig Lockhart, Benjamin Tan, W. Hawkins

I whakaputaina 2012

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
17

$Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors$

Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors mā Mark H. O’Hara, Wells A. Messersmith, Hedy L. Kindler, Wei Zhang, Celine Pitou, Anna M. Szpurka, Dan Wang, Sheng-Bin Peng, Burkhard Vangerow, Anis A. Khan, Mythili Koneru, Andrea Wang‐Gillam

I whakaputaina 2020

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
18

Surgical Outcome Results From SWOG S1505 mā Syed A. Ahmad, Mai Duong, Davendra Sohal, Namita Gandhi, Muhammad Shaalan Beg, Andrea Wang‐Gillam, James L. Wade, E. Gabriela Chiorean, Katherine A. Guthrie, Andrew M. Lowy, Philip A. Philip, Howard S. Höchster

I whakaputaina 2020

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
19

Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma mā Davendra Sohal, Mai Duong, Syed A. Ahmad, Namita Gandhi, Muhammad Shaalan Beg, Andrea Wang‐Gillam, James L. Wade, E. Gabriela Chiorean, Katherine A. Guthrie, Andrew M. Lowy, Philip A. Philip, Howard S. Höchster

I whakaputaina 2021

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
20

Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma mā Patrick Grierson, Benjamin Tan, Katrina S. Pedersen, Haeseong Park, Rama Suresh, Manik Amin, Nikolaos A. Trikalinos, Deborah Knoerzer, Brent Kreider, Anupama Reddy, Jingxia Liu, Channing J. Der, Andrea Wang‐Gillam, Kian‐Huat Lim

I whakaputaina 2022

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i: